Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 (Indacaterol + Glycopyrrolate) Phase 2 in COPD
NCT00570778Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2007
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 7. Started Dec 2007; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00570778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570778.